1. |
陈文虎, 方文涛, 蒋勇, 等. 贲门失弛症患者手术前后食管功能分析. 中华外科杂志, 1999, 2: 15-16.
|
2. |
陈文虎, 蒋勇, 周允中. 19例贲门癌术后食管腔内24小时pH监测结果分析. 中华胸心血管外科杂志, 1998, 1: 20-22.
|
3. |
陈文虎, 周允中, 黄偶麟, 等. 贲门失弛缓症218例手术结果分析. 医学研究通讯, 1997, 5: 42-44.
|
4. |
Ganz RA, Gostout CJ, Gruden J, et al. Use of a magnetic sphincter for the treatment of GERD: A feasibility study. Gastrointest Endosc, 2008, 67(2): 287-294.
|
5. |
Committee. GaUDpottMDa. LINX Reflux Management PMA briefing. 2012. Accessed on 25 Jan 2019. 网址?.
|
6. |
Lipham JC, Tgignides PA, Louie BE, et al. Safety analysis of first 1000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease. Dis Esophagus, 2015, 28(4): 305-311.
|
7. |
Asti E, Siboni S, Lazzari V, et al. Removal of the magnetic sphincter augmentation device: Surgical technique and results of a single-center cohort study. Ann Surg, 2017, 265(5): 941-945.
|
8. |
Vakil M, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophgeal reflux disease: A global evidence-based consensus. Am J Gastroenterol, 2006, 101: 1900-1920.
|
9. |
Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology, 2012, 143(5): 1179-1187.
|
10. |
El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut, 2014, 63(6): 871-880.
|
11. |
Becher A, El-Serag H. Systematic review: The association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2011, 34: 618-627.
|
12. |
Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol, 2009, 7: 372-378.
|
13. |
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology, 2017, 152(4): 706-715.
|
14. |
Fu S, Xu M, Zhou H, et al. Metabolic syndrome is associated with higher rate of gastroesophageal reflux disease: A meta-analysis. Neurogastroenterol Motil, 2022, 34(5): e14234.
|
15. |
Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med, 2022, 205(9): e18-e47.
|
16. |
Pandolfino JE, Richter JE, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol, 2003, 98(4): 740-749.
|
17. |
Streets CG, DeMeester TR, Peters JH, et al. Clinical evaluation of Bravo™ probe-a catheter-free ambulatory esophageal pH monitoring system. Gastroenterology, 2001, 120(5 Suppl 1): A35.
|
18. |
Belafsky PC, Allen K, Castro-Del Rosario L, et al. Wireless pH testing as an adjunct to unsedated transnasal esophagoscopy: The safety and efficacy of transnasal telemetry capsule placement. Otolaryngol Head Neck Surg, 2004, 131(1): 26-28.
|
19. |
Marchese M, Spada C, Iacopini F, et al. Nonendoscopic transnasal placement of a wireless capsule for esophageal pH monitoring: Feasibility, safety, and efficacy of a manometry-guided procedure. Endoscopy, 2006, 38(8): 813-818.
|
20. |
Ward EM, Devault KR, Bouras EP, et al. Successful oesophageal pH monitoring with a catheter-free system. Aliment Pharmacol Ther, 2004, 19: 449-454.
|